Home
Inbox
Search
Speaker
Roger Causon
PhD
Verona Pharma
Bookmark
Session(s)
Low Oral Bioavailability of RPL554, a First-in-Class Dual PDE3/4 Inhibitor, Demonstrates t...
Monday, May 21
11:15 AM - 1:00 PM
Home
Inbox
Search